We Think Genexine Has A Fair Chunk Of Debt - Simply Wall St
095700 Stock | KRW 5,880 230.00 4.07% |
About 55% of Genexine's investors are presently thinking to get in. The analysis of current outlook of investing in Genexine suggests that some traders are interested regarding Genexine's prospects. The current market sentiment, together with Genexine's historical and current headlines, can help investors time the market. In addition, many technical investors use Genexine stock news signals to limit their universe of possible portfolio assets.
Genexine |
We Think Genexine Has A Fair Chunk Of Debt Simply Wall St
Read at news.google.com
Genexine Fundamental Analysis
We analyze Genexine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genexine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genexine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Genexine is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Genexine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genexine stock to make a market-neutral strategy. Peer analysis of Genexine could also be used in its relative valuation, which is a method of valuing Genexine by comparing valuation metrics with similar companies.
Peers
Genexine Related Equities
086900 | Medy Tox | 2.17 | ||||
036200 | UNISEM | 1.65 | ||||
011390 | Busan Industrial | 0.89 | ||||
267250 | Hyundai Heavy | 0.62 | ||||
133820 | Fine Besteel | 0.71 | ||||
133820 | Finebesteel | 0.71 | ||||
012450 | Hanwha Aerospace | 11.00 |
Complementary Tools for Genexine Stock analysis
When running Genexine's price analysis, check to measure Genexine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genexine is operating at the current time. Most of Genexine's value examination focuses on studying past and present price action to predict the probability of Genexine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genexine's price. Additionally, you may evaluate how the addition of Genexine to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bonds Directory Find actively traded corporate debentures issued by US companies |